B+
Bull case
25%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
CRBP
CorbusANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$9.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$3.50
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-12
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+87.1
Score
AI commentary
The deterministic prior is positive and evidence quality is strong, but the setup is dominated by the September 14 CANYON-1 binary event. The webcast was announced after the September 11 price anchor, so the subsequent market reaction is unavailable. Recent company news is constructive on milestone timing, while the earnings miss, higher spending, insider sales, absent social coverage, and incomplete analyst-revision data argue for cautious positioning rather than treating missing evidence as positive.
RankAlpha Sentiment Codex - 2026-09-12
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-14eventCANYON-1 topline obesity dataHigh impact
Corbus scheduled a September 14 webcast to discuss topline results from the 240-participant, placebo-controlled Phase 1b CANYON-1 study of CRB-913. Weight-loss magnitude, dose response, tolerability, and neuropsychiatric safety could drive a binary valuation reset [#IR-2026-09-11].
2026-09-30catalystTEMPO-1 registrational-study enrollmentHigh impact
After FDA clearance, Corbus expected to commence enrollment in the 250-patient TEMPO-1 registrational study of CRB-701 in second-line oropharyngeal cancer during September 2026. Confirmed initiation would reduce timeline risk but remains less consequential than clinical efficacy data [#SEC-8K-2026-08-06].
2027-03-31catalystFirst-line CRB-701 combination dataHigh impact
Corbus anticipates CRB-701 plus Keytruda combination data in first-line OPSCC during Q1 2027 to inform potential additional registration-enabling trials; efficacy and safety will determine whether the oncology opportunity expands beyond the current second-line program [#PR-EARNINGS-2026-08-06].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-12 • Updated nightlySource: Internal modelMethodology